Board of Directors



Executive Director

Kevin Goodwin became CEO of Signostics in 2015 following multiple accomplishments in his 3-decade career as an innovator in the ultrasound industry. Most notably, he founded and served as CEO of the multinational point-of-care innovator SonoSite Inc., and capped his 17-year tenure there with its $1 billion sale to Fujifilm in 2012. Earlier, he held various managerial positions at ATL Ultrasound, Inc., including Vice President and General Manager of the company’s Handheld Systems Business Group.


Board Member

For over 25 years Mr. Keogh has assumed responsibilities in the stock brokerage industry, including direct management of client accounts, capital-raising with emerging companies, and corporate liaison with CEOs and senior management. Previously, he was Director of the High Net Worth Division at Bell Potter; Partner and Director of Southern Cross Equities; Director of Private Clients and Institutional Brokeringat CIBC; and Managing Partner at Eyres Reed Limited.


KKR, Member & Head of Health Care Industry Team – Americas

James Momtazee joined KKR in 1996 and is Head of the Health Care industry team and on the Investment Committee within KKR’s Americas Private Equity platform. He currently serves on the board of directors of Air Medical Group Holdings, Arbor Pharmaceuticals, BridgeBio, PRA Health Sciences and Signostics. He was also involved in the investments in HCA and Jazz Pharmaceuticals. Prior to joining KKR, Mr. Momtazee was with Donaldson, Lufkin & Jenrette where he worked on a broad range of corporate finance, mergers and acquisitions, and merchant banking transactions. He holds an A.B. with distinction, Phi Beta Kappa, from Stanford University and an M.B.A., Arjay Miller Scholar, from Stanford University Graduate School of Business.


Chairman of Board

Justin Sabet-Peyman joined KKR in 2008 and is a member of the Health Care industry team within KKR’s Private Equity platform. He currently serves on the board of directors of Signostics and as an observer on the board of Arbor Pharmaceuticals. He formerly served as a director on the board of Lake Region Medical before its sale to Greatbatch and has also been involved with KKR’s investments in Bayer Diabetes Care, Marvell Technology Group, Panasonic Healthcare, Go Daddy, and NXP. Prior to joining KKR, Mr. Sabet-Peyman worked at McKinsey & Company where he served several corporate and private equity clients. Justin received his B.S. and M.S. from Stanford University where he graduated as the Henry Ford II Scholar of the School of Engineering and was a Mayfield Fellow.